TINA GRIFFIN: Open Payments
NPI 1154945541 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,840 in 98 payments from 20 companies in 2025. Trend: 2023 $1,661 · 2024 $1,904 · 2025 $1,840
Food & beverage: $1,840
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 17 | $297 |
| Kowa Pharmaceuticals America, Inc. | 13 | $265 |
| AstraZeneca Pharmaceuticals LP | 14 | $227 |
| GlaxoSmithKline, LLC. | 8 | $153 |
| Novo Nordisk Inc | 11 | $149 |
| Amgen Inc. | 1 | $122 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| PFIZER INC. | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
Products named: ZORYVE, MOUNJARO, BREZTRI, SHINGRIX, OTEZLA, Ozempic, JARDIANCE, GEMTESA.
Industry payments across LA — which companies pay providers there.
